Cargando…

Cost-Effectiveness Analysis of Rivaroxaban in Chinese Patients With Stable Cardiovascular Disease

Objective: This study aimed to investigate the cost-effectiveness of low-dose rivaroxaban plus aspirin versus aspirin alone for patients with stable cardiovascular diseases in the China. Methods: We used TreeAge 2019 to construct a Markov model to assess the direct healthcare costs and quality-adjus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Tianyu, Zheng, Zhou, Gao, Shang, Xu, Jiaying, Cao, Pen, Jia, Huanhuan, Yu, Xihe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251332/ https://www.ncbi.nlm.nih.gov/pubmed/35795549 http://dx.doi.org/10.3389/fphar.2022.921387

Ejemplares similares

Cost-Effectiveness Analysis of the Helicobacter Pylori Screening Programme in an Asymptomatic Population in China
por: Feng, Tianyu, et al.
Publicado: (2022)

Ambient air pollution, temperature and hospital admissions due to respiratory diseases in a cold, industrial city
por: Jia, Huanhuan, et al.
Publicado: (2022)

The comparative analysis of SARIMA, Facebook Prophet, and LSTM for road traffic injury prediction in Northeast China
por: Feng, Tianyu, et al.
Publicado: (2022)

Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis
por: Chen, Can, et al.
Publicado: (2021)

Work Stress, Health Status and Presenteeism in Relation to Task Performance Among Chinese Medical Staff During COVID-19 Pandemic
por: Jia, Huanhuan, et al.
Publicado: (2022)

Factors Influencing Medical Personnel to Work in Primary Health Care Institutions: An Extended Theory of Planned Behavior
por: Jia, Huanhuan, et al.
Publicado: (2022)

Prevalence and Clustering of Cardiovascular Risk Factors among Medical Staff in Northeast China
por: Yu, Jianxing, et al.
Publicado: (2021)

Advances in the study of traditional Chinese medicine affecting bone metabolism through modulation of oxidative stress
por: Li, Jiaying, et al.
Publicado: (2023)

Evaluation of Herb–Drug Interaction Between Danshen and Rivaroxaban in Rat and Human Liver Microsomes
por: Wang, Xu, et al.
Publicado: (2022)

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
por: Wang, Zhi, et al.
Publicado: (2023)

The discovery of rivaroxaban: translating preclinical assessments into clinical practice
por: Kubitza, Dagmar, et al.
Publicado: (2013)

Corrigendum: Evaluation of herb–drug interaction between Danshen and rivaroxaban in rat and human liver microsomes
por: Wang, Xu, et al.
Publicado: (2022)

Rivaroxaban in heart failure patients with left ventricular thrombus: A retrospective study
por: Zhang, Qian, et al.
Publicado: (2022)

Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect
por: Ing Lorenzini, Kuntheavy, et al.
Publicado: (2016)

The mediating role of job satisfaction and presenteeism on the relationship between job stress and turnover intention among primary health care workers
por: Ning, Liangwen, et al.
Publicado: (2023)

Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting
por: Liang, Zhe, et al.
Publicado: (2021)

The relationship between public service motivation and turnover intention: the mediating role of work stress and task performance
por: Jia, Huanhuan, et al.
Publicado: (2022)

A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation
por: Zhao, Nan, et al.
Publicado: (2022)

Sequential Therapy of Nadroparin and Rivaroxaban in the Initial Treatment of Patients With Acute Pulmonary Embolism
por: Xiong, Wei, et al.
Publicado: (2022)

Rationale and design of a prospective study evaluating population pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non-valvular atrial fibrillation
por: Liu, Xiao-Qin, et al.
Publicado: (2022)

Prediction of Rivaroxaban-Rifampin Interaction After Major Orthopedic Surgery: Physiologically Based Pharmacokinetic Modeling and Simulation
por: Xu, Rui-juan, et al.
Publicado: (2021)

Serum Metabolomic Analysis of Coronary Heart Disease Patients with Stable Angina Pectoris Subtyped by Traditional Chinese Medicine Diagnostics Reveals Biomarkers Relevant to Personalized Treatments
por: Guo, Na, et al.
Publicado: (2021)

The Impact of Dabigatran and Rivaroxaban on Variation of Platelet Activation Biomarkers and DRT Following Percutaneous Left Atrial Appendage Closure
por: Li, Xiaoye, et al.
Publicado: (2021)

Single and Repeated Doses of EGb 761(®) do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects
por: Hoerr, Robert, et al.
Publicado: (2022)

Mental health among healthcare workers during the prolonged COVID-19 pandemic: A cross-sectional survey in Jilin Province in China
por: Ning, Liangwen, et al.
Publicado: (2022)

Therapeutic Effects of Traditional Chinese Medicine on Cardiovascular Diseases: the Central Role of Calcium Signaling
por: Li, Yuxin, et al.
Publicado: (2021)

Predicting Adverse Drug Events in Chinese Pediatric Inpatients With the Associated Risk Factors: A Machine Learning Study
por: Yu, Ze, et al.
Publicado: (2021)

Chinese Herbal Medicine on Cardiovascular Diseases and the Mechanisms of Action
por: Liu, Cuiqing, et al.
Publicado: (2016)

Influence of ABCB1 Gene Polymorphism on Rivaroxaban Blood Concentration and Hemorrhagic Events in Patients With Atrial Fibrillation
por: Wang, Yan, et al.
Publicado: (2021)

Evaluation of Remote Pharmacist-Led Outpatient Service for Geriatric Patients on Rivaroxaban for Nonvalvular Atrial Fibrillation During the COVID-19 Pandemic
por: Li, Xiaoye, et al.
Publicado: (2020)

Clinical Efficacy and Safety Comparison of Rivaroxaban and Dabigatran for Nonvalvular Atrial Fibrillation Patients Undergoing Percutaneous Left Atrial Appendage Closure Operation
por: Li, Xiaoye, et al.
Publicado: (2021)

Quantitative Systems Pharmacology Model-Based Predictions of Clinical Endpoints to Optimize Warfarin and Rivaroxaban Anti-Thrombosis Therapy
por: Hartmann, Sonja, et al.
Publicado: (2020)

Plasma Rivaroxaban Level in Patients With Early Stages of Chronic Kidney Disease—Relationships With Renal Function and Clinical Events
por: Sin, Chun-Fung, et al.
Publicado: (2022)

Effect of Traditional Chinese Medicine on the Cardiovascular Diseases
por: Jiang, Yang, et al.
Publicado: (2022)

Application of network pharmacology in the study of the mechanism of action of traditional chinese medicine in the treatment of COVID-19
por: Zheng, Shihao, et al.
Publicado: (2022)

Analysis of factors affecting medical personnel seeking employment at primary health care institutions: developing human resources for primary health care
por: Jia, Huanhuan, et al.
Publicado: (2022)

Traditional Chinese Medicine as a Promising Strategy for the Treatment of Alzheimer’s Disease Complicated With Osteoporosis
por: Xu, Weifan, et al.
Publicado: (2022)

International Normalized Ratio as a Screening Test for Assessment of Anticoagulant Activity for Patients Treated With Rivaroxaban or Apixaban: A Pilot Study
por: Ofek, Fanny, et al.
Publicado: (2019)

Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study
por: Grymonprez, Maxim, et al.
Publicado: (2023)

Population Pharmacokinetics of Mycophenolic Acid in Renal Transplant Patients: A Comparison of the Early and Stable Posttransplant Stages
por: Wang, Peile, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kdisr5g7or1lii5d1vuhj9vol6